Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Wearable eye-tracker aims to catch dizziness in the act

NCT ID NCT04026516

Diagnosis Sponsor: Norfolk and Norwich University Hospitals NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial tests a wearable device called CAVA that records eye and head movements for 30 days in people with dizziness conditions like Meniere's disease and BPPV. The goal is to see if the device can accurately detect episodes of nystagmus, an eye movement linked to dizziness, and help identify when dizzy events occur. Participants wear the device almost all day, and researchers compare the device's findings with reported dizzy episodes to measure its accuracy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CAVA device, a wearable that records eye and head movements continuously for 30 days
What this could lead to
If successful, this could lead to a reliable, home-based diagnostic tool for dizziness conditions, reducing the need for clinic visits.
What could go wrong
The trial is small and early-stage, and the device's accuracy in detecting nystagmus may not reach the target of 95%, or it may be uncomfortable for long-term wear.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

29 people

The number who actually took part.

Started

Jul 2019

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Adults aged 18 and over. * Patients experiencing episodes of true vertigo, with at least two episodes within the preceding month. Relevant medical conditions include Meniere's disease, Benign Paroxysmal Positional Vertigo (BPPV), recurrent vestibulopathy and vestibular migraine. * Able to commit to 30 days of continuous wear of the trial device as per the study plan. * Own a telephone. Exclusion Criteria: * Potential participants who have a history of dermatological disease, fragile skin, or damage around the forehead. * Potential participants who have an allergy to plasters and/or medical adhesives - (similarly to materials used in the device). * History of hypertension or cardiac problems (uncontrolled, acute or de-compensated - phase). * History of ear disease, or previous ear surgery. * History of psychotic/neurotic disorders or epilepsy. * History of eye disease, or previous eye surgery. * Pregnant or nursing mothers. * Potential participants who have taken part in a previous CAVA trial. * Potential participants who are currently taking part in another trial. * Unable to follow the testing protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Benign paroxysmal positional vertigo are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

benign paroxysmal positional vertigo Meniere disease migraine with brainstem aura pathologic nystagmus vestibular neuronitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Benign paroxysmal positional vertigo Meniere's disease Recurrent vestibulopathy Vestibular migraine

Contacts and locations

Locations

  • Norfolk & Norwich University Hospitals NHS Foundation Trust

    Norwich, Norfolk, NR4 7UY, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.